HUP0303622A2 - Terápiás hatóanyagok gyulladásos bélbetegségek kezelésére - Google Patents
Terápiás hatóanyagok gyulladásos bélbetegségek kezeléséreInfo
- Publication number
- HUP0303622A2 HUP0303622A2 HU0303622A HUP0303622A HUP0303622A2 HU P0303622 A2 HUP0303622 A2 HU P0303622A2 HU 0303622 A HU0303622 A HU 0303622A HU P0303622 A HUP0303622 A HU P0303622A HU P0303622 A2 HUP0303622 A2 HU P0303622A2
- Authority
- HU
- Hungary
- Prior art keywords
- ailim
- activity
- inflammatory bowel
- modulating
- subject
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 206010057248 Cell death Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000017307 interleukin-4 production Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
A találmány tárgyát olyan anyagot tartalmazó gyógyászati készítményekképezik, amely <aktiválással indukálható limfocita-immunmodulátormolekula< (AILIM),[amely <indukálható kostimulátor< (ICOS) névenszintén ismert] biológiai aktivitását modulálni képes aktivitással,közelebbről AILIM-mediált jelátvitelt modulálni képes aktivitássalrendelkezik. A találmány tárgyát közelebbről olyan anyagot tartalmazógyógyászati készítmények képezik, amely AILIM-et expresszáló sejtekproliferációját, sejtpusztulást (vagy apoptózist) vagy immun-citolízist szabályzó (például gátló) aktivitással rendelkezik, vagyAILIM-et expresszáló sejtek citokintermelését (például interferon-g-,interleukin-4-termelését) modulálni (például gátolni) képesaktivitással rendelkezik. A találmány szerinti gyógyászatikészítmények alkalmasak a béltraktus abnormális immunitását kísérőbetegségek[például gyulladásos bélbetegségek, példáulvastagbélgyulladás (kifekélyesedő vastagbélgyulladás és hasonlók), ésCrohn-betegség, valamint ételallergiák] szuppresszálására, kezelésérevagy prevenciójára. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001089158 | 2001-03-27 | ||
JP2002019291A JP4210454B2 (ja) | 2001-03-27 | 2002-01-29 | 炎症性腸疾患治療剤 |
PCT/JP2002/001361 WO2002076504A1 (fr) | 2001-03-27 | 2002-02-18 | Remedes contre les affections intestinales inflammatoires |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0303622A2 true HUP0303622A2 (hu) | 2004-01-28 |
HUP0303622A3 HUP0303622A3 (en) | 2008-11-28 |
HU229378B1 HU229378B1 (en) | 2013-11-28 |
Family
ID=26612136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303622A HU229378B1 (en) | 2001-03-27 | 2002-02-18 | Remedies for inflammatory bowel diseases |
Country Status (18)
Country | Link |
---|---|
US (2) | US7465444B2 (hu) |
EP (1) | EP1374902B1 (hu) |
JP (1) | JP4210454B2 (hu) |
KR (1) | KR100602940B1 (hu) |
CN (1) | CN1291757C (hu) |
AT (1) | ATE510562T1 (hu) |
AU (1) | AU2002232222B8 (hu) |
BR (1) | BR0208446A (hu) |
CA (1) | CA2441577C (hu) |
CZ (1) | CZ20032692A3 (hu) |
HU (1) | HU229378B1 (hu) |
IL (2) | IL158088A0 (hu) |
MX (1) | MXPA03008760A (hu) |
NO (1) | NO332316B1 (hu) |
NZ (1) | NZ528554A (hu) |
RU (1) | RU2281118C2 (hu) |
SK (1) | SK288036B6 (hu) |
WO (1) | WO2002076504A1 (hu) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7749714B2 (en) * | 2003-03-12 | 2010-07-06 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating prostate cancer |
WO2005103086A1 (en) * | 2004-04-23 | 2005-11-03 | Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
NZ625807A (en) * | 2005-07-18 | 2015-11-27 | Amgen Inc | Human anti-b7rp1 neutralizing antibodies |
AU2013203437A1 (en) * | 2005-07-18 | 2013-05-02 | Amgen Inc. | Human anti-B7RP1 neutralizing antibodies |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
RS56049B1 (sr) * | 2008-11-13 | 2017-09-29 | Nogra Pharma Ltd | Antisens kompozicije i postupci za pripremu i upotrebu istih |
JP6220774B2 (ja) * | 2011-03-31 | 2017-10-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Icosに対する抗体及びその使用 |
US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
MD480Z (en) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Method for treating acute ulcerative nonspecific colitis |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
UA118750C2 (uk) | 2013-03-15 | 2019-03-11 | Ґлаксосмітклайн Інтеллектуал Проперті Дивелопмент Лімітед | Антитіло до lag-3 |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
SG10201913864RA (en) | 2015-09-02 | 2020-03-30 | Immutep Sas | Anti-LAG-3 Antibodies |
EP3366691A1 (en) | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
AU2017247806B2 (en) | 2016-04-07 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
CA3019630A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
US10604531B2 (en) | 2016-05-05 | 2020-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
CA3031047A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
CA3052767A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
WO2018225033A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
WO2019053613A2 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質(sting)の調節物質 |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
CN112469416A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用于治疗癌症的ii型蛋白质精氨酸甲基转移酶抑制剂和icos结合蛋白的组合 |
BR112020023459A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada com proteínas de ligação a icos e inibidores de arginina metiltransferase |
KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
MX2021004603A (es) | 2018-10-22 | 2021-09-08 | Glaxosmithkline Ip Dev Ltd | Dosificacion. |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
EP4034562A2 (en) | 2019-09-27 | 2022-08-03 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN115698075A (zh) | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体,任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
US20230149543A1 (en) | 2020-04-14 | 2023-05-18 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein |
WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
CN116917273A (zh) | 2021-03-02 | 2023-10-20 | 葛兰素史克知识产权发展有限公司 | 作为dnmt1抑制剂的经取代的吡啶 |
IL305081A (en) * | 2021-03-12 | 2023-10-01 | Adaptive Biotechnologies Corp | T-cell receptor-related methods are associated with Crohn's disease |
KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
CA2242414C (en) | 1996-01-23 | 2012-01-03 | Genentech, Inc. | Anti-cd18 antibodies for use against stroke |
US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
NZ334714A (en) | 1996-09-18 | 2000-08-25 | Zetesis Spa | Liver proteins as agents against autoimmune diseases |
EP1878748A2 (en) * | 1996-11-08 | 2008-01-16 | Biogen Idec Inc. | Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 costimulatory antigens |
AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
JP4463418B2 (ja) * | 1997-09-23 | 2010-05-19 | ドイツ連邦共和国 | T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
JP2000154151A (ja) | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
WO2000019988A1 (en) | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
SI2332976T1 (sl) * | 1999-02-03 | 2014-08-29 | Amgen Inc. | Novi polipeptidi, vkljuäśeni v imunskem odgovoru |
US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
CA2373256A1 (en) | 1999-05-06 | 2000-11-16 | Genetics Institute, Inc. | Use of soluble costimulatory molecules to enhance immune responses |
WO2001008700A1 (en) | 1999-07-28 | 2001-02-08 | Genetics Institute, Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
WO2001012658A2 (en) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
EP1212343A4 (en) | 1999-09-03 | 2004-11-03 | Human Genome Sciences Inc | 52 HUMAN SECRETED PROTEINS |
WO2001021796A2 (en) | 1999-09-21 | 2001-03-29 | Genetics Institute, Inc. | Gl50 molecules and uses therefor |
AU1342501A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 32 human secreted proteins |
AU2001245396A1 (en) | 2000-03-02 | 2001-09-12 | Mayo Foundation For Medical Education And Research | Hb7-h2, a novel co-stimulatory molecule |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
AU1796902A (en) | 2000-11-28 | 2002-06-11 | Amgen Inc | Novel polypeptides involved in immune response |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US7428905B2 (en) * | 2004-07-30 | 2008-09-30 | R.J. Reynolds Tobacco Company | Method of making smokeable tobacco substitute filler having an increased fill value |
-
2002
- 2002-01-29 JP JP2002019291A patent/JP4210454B2/ja not_active Expired - Fee Related
- 2002-02-18 IL IL15808802A patent/IL158088A0/xx unknown
- 2002-02-18 AT AT02712418T patent/ATE510562T1/de not_active IP Right Cessation
- 2002-02-18 HU HU0303622A patent/HU229378B1/hu not_active IP Right Cessation
- 2002-02-18 EP EP02712418A patent/EP1374902B1/en not_active Expired - Lifetime
- 2002-02-18 NZ NZ528554A patent/NZ528554A/en not_active IP Right Cessation
- 2002-02-18 CN CNB028107470A patent/CN1291757C/zh not_active Expired - Fee Related
- 2002-02-18 KR KR1020037012380A patent/KR100602940B1/ko not_active IP Right Cessation
- 2002-02-18 US US10/472,743 patent/US7465444B2/en not_active Expired - Fee Related
- 2002-02-18 WO PCT/JP2002/001361 patent/WO2002076504A1/ja active IP Right Grant
- 2002-02-18 BR BR0208446-5A patent/BR0208446A/pt not_active Application Discontinuation
- 2002-02-18 MX MXPA03008760A patent/MXPA03008760A/es active IP Right Grant
- 2002-02-18 AU AU2002232222A patent/AU2002232222B8/en not_active Ceased
- 2002-02-18 SK SK1330-2003A patent/SK288036B6/sk not_active IP Right Cessation
- 2002-02-18 CA CA2441577A patent/CA2441577C/en not_active Expired - Fee Related
- 2002-02-18 CZ CZ20032692A patent/CZ20032692A3/cs unknown
- 2002-02-18 RU RU2003131330/15A patent/RU2281118C2/ru active
-
2003
- 2003-09-24 IL IL158088A patent/IL158088A/en not_active IP Right Cessation
- 2003-09-26 NO NO20034312A patent/NO332316B1/no not_active IP Right Cessation
-
2008
- 2008-11-11 US US12/268,882 patent/US8052972B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303622A2 (hu) | Terápiás hatóanyagok gyulladásos bélbetegségek kezelésére | |
Lazar et al. | Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer | |
HUP0002224A1 (hu) | Virusellenes hatású benzimidazol-származékok | |
TR200101204T2 (tr) | Dialkil Fumaratlarının kullanımı | |
HUP0002196A2 (hu) | Gyógyhatású táplálékkiegészítő cukorbetegek részére | |
IL173684A0 (en) | Disodium-4,4'-azo-bis-salicylate and pharmaceutical compositions containing the same | |
HUP0402370A2 (hu) | Ciklooxigenáz-2 inhibitor és hiszton deacetiláz inhibitor keverékét tartalmazó gyógyszerkészítmények | |
Matar et al. | Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response | |
GR862201B (en) | Polypeptides and antibodies characteristic of papillomavirus and their application to in vitro diagnosis the prevention and the fight against the infections by the papillomavirus | |
Heo et al. | Anticlastogenic effects of galangin against bleomycin-induced chromosomal aberrations in mouse spleen lymphocytes | |
DE69841200D1 (de) | Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten | |
EE03771B1 (et) | Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine | |
DK0820303T3 (da) | p277 peptidanaloger og farmaceutiske sammensætninger, der omfatter dem, til behandling eller diagnosticering af diabetes | |
MA26792A1 (fr) | Composition comportant la sphingomyelinase alcaline a utiliser comme preparation dietetique , supplement alimentaire ou produit pharmaceutique. | |
EA200000240A1 (ru) | Соединения, препятствующие эффекту раннего превращения лекарственных средств | |
Nishi et al. | Vitamin C prevents DNA damage induced by renovascular hypertension in multiple organs of Wistar rats | |
ES2144054T3 (es) | Complejos de tri(platino). | |
HUP0202692A2 (hu) | Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
Zhu et al. | Gene expression of sHsps, Hsp40 and Hsp60 families in normal and abnormal embryonic development of mouse forelimbs | |
PT951553E (pt) | Proteinas de e4 de adenovirus para unducao de morte celular | |
Ashique et al. | Recent updates on correlation between reactive oxygen species and synbiotics for effective management of ulcerative colitis | |
Salimonu et al. | Depressed natural killer cell activity in children with protein-calorie malnutrition: II. Correction of the impaired activity after nutritional recovery | |
Han et al. | Disparity in the production of lymphoblastogenesis inhibition factor by cultured human B and T lymphoid cell lines. | |
AU2002326070A1 (en) | Peyers's patch and/or m-celle targeting ligands | |
MX9803610A (es) | Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of definitive patent protection due to non-payment of fees |